Abstract: The invention includes a formulation of a therapeutic compound, wherein release of the therapeutic compound from the formulation coincides with peak or trough expression of at least one target gene of the therapeutic compound. The invention also includes a method of developing such formulations and a method of treating a disorder in a subject using such formulations.

Abstract: The invention includes a formulation of a therapeutic compound, wherein release of the therapeutic compound from the formulation coincides with peak or trough expression of at least one target gene of the therapeutic compound. The invention also includes a method of developing such formulations and a method of treating a disorder in a subject using such formulations.

Abstract: The invention is drawn to a new class of isoeicosanoids that have been identified as products of the oxidation of docosahexaenoic acid (DHA). The invention provides compositions and methods related to the new class of molecules.

Abstract: The invention relates to compositions and methods for regulating hair growth. Specifically, the invention relates to regulating hair growth by regulating the activity one of the prostaglandin D2 (PGD2) receptors, DP-2 (GPR44). Compositions and methods for regulating hair growth include inhibiting hair growth by administering a DP-2 agonist, or stimulating hair growth by administering a DP-2 antagonist.

Abstract: The present invention relates to a prostaglandin D2 metabolite, derivatives thereof, compositions comprising the metabolite, and an antibody that specially binds to the metabolite. Methods of use are also provided.

Abstract: The present invention relates to methods for identifying candidate therapeutics for hypertension. The invention further provides a method for treating hypertension and/or decreasing atherogenesis by administration of an inhibitor of PGF2? receptor.

Abstract: The instant invention is drawn to methods and compositions useful for the assessment of cardiovascular risk in a mammal. The methods utilize biomarkers including prostanoid metabolites and isoprostanes as sensitive and stable markers of cardiovascular risk. The methods are particularly useful in a mammal that is contemplating undergoing coxib therapy, is undergoing coxib therapy, is undergoing antioxidant therapy, has ceased coxib therapy or has never undergone coxib therapy. The invention also includes kits useful for the assessment of cardiovascular risk in a mammal.

Abstract: The invention is drawn to a new class of isoeicosanoids that have been identified as products of the oxidation of docosahexaenoic acid (DHA). The invention provides compositions and methods related to the new class of molecules.

Abstract: The present invention relates to a prostaglandin D2 metabolite, derivatives thereof, compositions comprising the metabolite, and an antibody that specially binds to the metabolite. Methods of use are also provided.

Abstract: The present invention relates to methods for the treatment of inflammation and pain without increasing cardiovascular risk by administration of an inhibitor of mPGES-1. The invention further is related to identifying inhibitors of mPGES-1 that do not increase cardiovascular risk when administered to an individual.

Abstract: The present invention relates to methods for the treatment of inflammation and pain without increasing cardiovascular risk by administration of an inhibitor of mPGES-1. The invention further is related to identifying inhibitors of mPGES-1 that do not increase cardiovascular risk when administered to an individual.

Abstract: The present invention provides methods of effecting a change in the core circadian clock by modulating retinoid nuclear receptors.

Abstract: The instant invention is drawn to methods and compositions useful for the assessment of cardiovascular risk in a mammal. The methods utilize biomarkers including prostanoid metabolites and isoprostanes as sensitive and stable markers of cardiovascular risk. The methods are particularly useful in a mammal that is contemplating undergoing coxib therapy, is undergoing coxib therapy, is undergoing antioxidant therapy, has ceased coxib therapy or has never undergone coxib therapy. The invention also includes kits useful for the assessment of cardiovascular risk in a mammal.

Abstract: The invention includes methods useful for the diagnosis of Alzheimer's disease and the evaluation of enhanced levels of lipid peroxidation in a mammal. The methods utilize isoprostanes as sensitive and stable molecular markers for lipid peroxidation in a mammal. Methods of identifying compounds useful for the treatment of Alzheimer's disease or for reducing levels of lipid peroxidation in a mammal are also included. The invention also includes kits useful for the diagnosis of Alzheimer's disease and for the evaluation of levels of lipid peroxidation in a mammal.

Abstract: The invention includes methods useful for the diagnosis of Alzheimer's disease and the evaluation of enhanced levels of lipid peroxidation in a mammal. The methods utilize isoprostanes as sensitive and stable molecular markers for lipid peroxidation in a mammal. Methods of identifying compounds useful for the treatment of Alzheimer's disease or for reducing levels of lipid peroxidation in a mammal are also included. The invention also includes kits useful for the diagnosis of Alzheimer's disease and for the evaluation of levels of lipid peroxidation in a mammal.

Abstract: The present invention provides methods of effecting a change in the core circadian clock by modulating retinoid nuclear receptors.

Abstract: The invention includes methods useful for the diagnosis of Alzheimer's disease and the evaluation of enhanced levels of lipid peroxidation in a mammal. The methods utilize isoprostanes as sensitive and stable molecular markers for lipid peroxidation in a mammal. Methods of identifying compounds useful for the treatment of Alzheimer's disease or for reducing levels of lipid peroxidation in a mammal are also included. The invention also includes kits useful for the diagnosis of Alzheimer's disease and for the evaluation of levels of lipid peroxidation in a mammal.